{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:41:17Z","timestamp":1788352877088,"version":"build-2803163510"},"reference-count":16,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2024,9,17]]},"DOI":"10.1001\/jama.2024.8819","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T15:01:53Z","timestamp":1721660513000},"page":"877","source":"Crossref","is-referenced-by-count":4,"title":["Monoclonal Antibody Risankizumab for Ulcerative Colitis"],"prefix":"10.1001","volume":"332","author":[{"given":"Gilaad G.","family":"Kaplan","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10","key":"jed240042r1","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1001\/jama.2023.15389","article-title":"Ulcerative colitis in adults: a review.","volume":"330","author":"Gros","year":"2023","journal-title":"JAMA"},{"key":"jed240042r2","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002687","article-title":"Forecasting the incidence and prevalence of inflammatory bowel disease: a Canadian nationwide analysis.","author":"Coward","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"jed240042r3","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1053\/j.gastro.2023.07.003","article-title":"Incidence, prevalence, and racial and ethnic distribution of inflammatory bowel disease in the United States.","volume":"165","author":"Lewis","year":"2023","journal-title":"Gastroenterology"},{"issue":"6","key":"jed240042r4","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1007\/s10620-021-07200-1","article-title":"Systematic review and meta-analysis: risk of hospitalization in patients with ulcerative colitis and Crohn\u2019s disease in population-based cohort studies.","volume":"67","author":"Tsai","year":"2022","journal-title":"Dig Dis Sci"},{"issue":"10","key":"jed240042r5","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/j.cgh.2020.10.039","article-title":"Contemporary risk of surgery in patients with ulcerative colitis and Crohn\u2019s disease: a meta-analysis of population-based cohorts.","volume":"19","author":"Tsai","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"jed240042r6","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/S2468-1253(23)00003-1","article-title":"The cost of inflammatory bowel disease in high-income settings: a Lancet gastroenterology and hepatology commission.","volume":"8","author":"Burisch","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"jed240042r7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment.","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"issue":"2","key":"jed240042r8","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41575-022-00738-z","article-title":"Improving IBD outcomes in the era of many treatment options.","volume":"20","author":"Kobayashi","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"jed240042r9","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1053\/j.gastro.2021.09.078","article-title":"Breaking through the therapeutic ceiling: what will it take?","volume":"162","author":"Raine","year":"2022","journal-title":"Gastroenterology"},{"issue":"13","key":"jed240042r10","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis.","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"issue":"26","key":"jed240042r11","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as induction and maintenance therapy for ulcerative colitis.","volume":"388","author":"D\u2019Haens","year":"2023","journal-title":"N Engl J Med"},{"key":"jed240042r12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.12414","article-title":"Risankizumab for ulcerative colitis: two randomized clinical trials.","author":"Louis","journal-title":"JAMA"},{"issue":"10340","key":"jed240042r13","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(22)00466-4","article-title":"Risankizumab as maintenance therapy for moderately to severely active Crohn\u2019s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.","volume":"399","author":"Ferrante","year":"2022","journal-title":"Lancet"},{"issue":"6","key":"jed240042r14","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/j.cgh.2023.11.033","article-title":"Risankizumab effectiveness and safety in Crohn\u2019s disease: real-world data from a large tertiary center.","volume":"22","author":"Zinger","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12S","key":"jed240042r15","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.14309\/01.ajg.0000995740.88073.c5","article-title":"S1 risankizumab versus ustekinumab in patients with moderate to severe Crohn\u2019s disease: results from the phase 3B SEQUENCE trial.","volume":"118","author":"Peyrin-Biroulet","year":"2023","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"jed240042r16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s11894-023-00913-5","article-title":"Biosimilars in IBD: what every clinician needs to know.","volume":"26","author":"Angyal","year":"2024","journal-title":"Curr Gastroenterol Rep"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2821294\/jama_kaplan_2024_ed_240042_1725904458.55483.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T16:31:07Z","timestamp":1726590667000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2821294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,17]]},"references-count":16,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,9,17]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2024.8819","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,17]]}}}